{"id":235009,"date":"2021-02-21T13:04:17","date_gmt":"2021-02-21T18:04:17","guid":{"rendered":"https:\/\/oncubanews.com\/en\/?p=235009"},"modified":"2021-02-21T13:04:17","modified_gmt":"2021-02-21T18:04:17","slug":"soberana-02-vaccine-candidate-starts-large-scale-production","status":"publish","type":"post","link":"https:\/\/oncubanews.com\/en\/cuba\/soberana-02-vaccine-candidate-starts-large-scale-production\/","title":{"rendered":"Soberana 02 vaccine candidate starts large-scale production"},"content":{"rendered":"

The large-scale production of the Cuban <\/span>Soberana 02<\/span><\/a> COVID-19 vaccine candidate has started at the National Center for Biopreparations (Biocen), authorities from the BioCubaFarma business group and the Finlay Vaccine Institute confirmed.<\/span><\/p>\n

It was learned in a <\/span>note published<\/span><\/a> by the official media on the island that the mass production of this prototype in <\/span>Biocen<\/span><\/a>\u2019s bioparent plant is due to its upcoming use during phase III of clinical trials, which should begin in March.<\/span><\/p>\n

The note says that Soberana 02 is the most advanced of the four vaccine candidates that are in different stages of clinical trials, all with positive results at the moment: Soberana 01, Mambisa and Abdala.<\/span><\/p>\n

The current health emergency being experienced by Cuba and the rest of the planet due to the SARS-CoV-2 virus makes the production of these products a challenge for Cuban science, always complying with quality standards and with sufficient productive capacities, the source specified.<\/span><\/p>\n

\n

Presidente de #BioCubaFarma<\/a> junto a otros directivos del sector realiza recorrido por la Planta de Parenterales de @BIOCENCU<\/a>, donde ya se est\u00e1 produciendo a gran escala la #Soberana02<\/a> que se utilizar\u00e1 en el Ensayo Cl\u00ednico Fase III. #CubaViva<\/a> pic.twitter.com\/G698BRZvYP<\/a><\/p>\n

— BioCubaFarma (@BioCubaFarma) February 20, 2021<\/a><\/p><\/blockquote>\n